Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| KYNTRA BIO, INC.FGEN · Entity 7431 | Director · Chief Executive Officer | August 21, 2019 | August 23, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
KYNTRA BIO, INC.
Report date August 21, 2019 · Filed August 23, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,326,612 |
Ending reported balance
After 2019-08-22 transaction · row 6
5 source rows · reconciled sequenceRow 1 · 2019-08-21 · Exercise / conversion · Acquired 6,834 · Balance 2,356,578 Row 2 · 2019-08-21 · Sale · Disposed 18,400 · Balance 2,338,178 F1: Shares sold pursuant to a 10b5-1 plan. F2: The shares were sold at prices ranging from $44.54 to $45.12. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 4 · 2019-08-22 · Exercise / conversion · Acquired 6,834 · Balance 2,345,012 Row 5 · 2019-08-22 · Sale · Disposed 17,100 · Balance 2,327,912 F1: Shares sold pursuant to a 10b5-1 plan. F4: The shares were sold at prices ranging from $43.46 to $44.38. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 6 · 2019-08-22 · Sale · Disposed 1,300 · Balance 2,326,612 F1: Shares sold pursuant to a 10b5-1 plan. F5: The shares were sold at prices ranging from $44.61 to $44.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Common StockSEC Table I · non-derivative | IndirectBy Family Partnership | 45,656 |
Reported balance
After 2019-08-21 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2019-08-21 · Sale · Disposed 1,418 · Balance 45,656 F1: Shares sold pursuant to a 10b5-1 plan. F3: The shares were sold at prices ranging from $44.51 to $45.115. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Common StockSEC Table I · non-derivative | IndirectBy Family Partnership | 44,238 |
Reported balance
After 2019-08-22 transaction · row 7
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 7 · 2019-08-22 · Sale · Disposed 1,418 · Balance 44,238 F1: Shares sold pursuant to a 10b5-1 plan. F6: The shares were sold at prices ranging from $43.47 to $43.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.90 · Expires 2020-06-09 | Direct | 184,536 |
Reported balance
After 2019-08-21 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-08-21 · Exercise / conversion · Disposed 6,834 · Balance 184,536 F8: Fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.90 · Expires 2020-06-09 | Direct | 177,702 |
Reported balance
After 2019-08-22 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2019-08-22 · Exercise / conversion · Disposed 6,834 · Balance 177,702 F8: Fully vested. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 20,000 |
Reported balance
Holding disclosure · report date 2019-08-21 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 20,000 |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 60,946 |
Reported balance
Holding disclosure · report date 2019-08-21 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 60,946 F7: The shares are held by BioGrowth Partners, LP. The reporting person is the sole general partner of BioGrowth Partners, LP and has sole voting and dispositive power over the shares held by BioGrowth Partners, LP. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold pursuant to a 10b5-1 plan.
F2: The shares were sold at prices ranging from $44.54 to $45.12. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3: The shares were sold at prices ranging from $44.51 to $45.115. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4: The shares were sold at prices ranging from $43.46 to $44.38. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5: The shares were sold at prices ranging from $44.61 to $44.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F6: The shares were sold at prices ranging from $43.47 to $43.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F7: The shares are held by BioGrowth Partners, LP. The reporting person is the sole general partner of BioGrowth Partners, LP and has sole voting and dispositive power over the shares held by BioGrowth Partners, LP.
F8: Fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 22, 2019 Filed Aug 23, 2019 20:49 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,834 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-19-047314 · doc4.xml · derivative · entry 11 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,702 Underlying: Common Stock · 6,834 shares Expires 2020-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully vested. Read SEC document |
| August 22, 2019 Filed Aug 23, 2019 20:49 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,418 | $43.77 | $62,065.86 |
DisclosureSEC source: 0001209191-19-047314 · doc4.xml · nonDerivative · entry 7 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 44,238 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F6 · price: The shares were sold at prices ranging from $43.47 to $43.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 22, 2019 Filed Aug 23, 2019 20:49 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,300 | $44.73 | $58,149.00 |
DisclosureSEC source: 0001209191-19-047314 · doc4.xml · nonDerivative · entry 6 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,326,612 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F5 · price: The shares were sold at prices ranging from $44.61 to $44.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 22, 2019 Filed Aug 23, 2019 20:49 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 17,100 | $43.80 | $748,980.00 |
DisclosureSEC source: 0001209191-19-047314 · doc4.xml · nonDerivative · entry 5 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,327,912 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $43.46 to $44.38. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 22, 2019 Filed Aug 23, 2019 20:49 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 6,834 | $2.90 | $19,818.60 |
DisclosureSEC source: 0001209191-19-047314 · doc4.xml · nonDerivative · entry 4 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,345,012 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 21, 2019 Filed Aug 23, 2019 20:49 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,834 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-19-047314 · doc4.xml · derivative · entry 10 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,536 Underlying: Common Stock · 6,834 shares Expires 2020-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully vested. Read SEC document |
| August 21, 2019 Filed Aug 23, 2019 20:49 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,418 | $44.81 | $63,540.58 |
DisclosureSEC source: 0001209191-19-047314 · doc4.xml · nonDerivative · entry 3 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 45,656 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $44.51 to $45.115. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 21, 2019 Filed Aug 23, 2019 20:49 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 18,400 | $44.79 | $824,136.00 |
DisclosureSEC source: 0001209191-19-047314 · doc4.xml · nonDerivative · entry 2 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,338,178 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $44.54 to $45.12. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 21, 2019 Filed Aug 23, 2019 20:49 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 6,834 | $2.90 | $19,818.60 |
DisclosureSEC source: 0001209191-19-047314 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,356,578 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 13, 2019 Filed Aug 14, 2019 21:38 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,834 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-19-045973 · doc4.xml · derivative · entry 14 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,370 Underlying: Common Stock · 6,834 shares Expires 2020-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Fully vested. Read SEC document |
| August 13, 2019 Filed Aug 14, 2019 21:38 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 500 | $46.17 | $23,085.00 |
DisclosureSEC source: 0001209191-19-045973 · doc4.xml · nonDerivative · entry 10 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 47,074 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F9 · price: The shares were sold at prices ranging from $46.00 to $46.37. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 13, 2019 Filed Aug 14, 2019 21:38 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 918 | $45.31 | $41,594.58 |
DisclosureSEC source: 0001209191-19-045973 · doc4.xml · nonDerivative · entry 9 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 47,574 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F8 · price: The shares were sold at prices ranging from $44.98 to $45.82. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 13, 2019 Filed Aug 14, 2019 21:38 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 6,900 | $46.19 | $318,711.00 |
DisclosureSEC source: 0001209191-19-045973 · doc4.xml · nonDerivative · entry 8 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,349,744 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F7 · price: The shares were sold at prices ranging from $45.94 to $46.60. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 13, 2019 Filed Aug 14, 2019 21:38 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 11,500 | $45.33 | $521,295.00 |
DisclosureSEC source: 0001209191-19-045973 · doc4.xml · nonDerivative · entry 7 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,356,644 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F6 · price: The shares were sold at prices ranging from $44.94 to $45.93. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 13, 2019 Filed Aug 14, 2019 21:38 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 6,834 | $2.90 | $19,818.60 |
DisclosureSEC source: 0001209191-19-045973 · doc4.xml · nonDerivative · entry 6 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,368,144 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 21:38 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,834 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-19-045973 · doc4.xml · derivative · entry 13 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,204 Underlying: Common Stock · 6,834 shares Expires 2020-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Fully vested. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 21:38 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 300 | $45.67 | $13,701.00 |
DisclosureSEC source: 0001209191-19-045973 · doc4.xml · nonDerivative · entry 5 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 48,492 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F5 · price: The shares were sold at prices ranging from $45.515 to $45.76. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 21:38 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,118 | $45.04 | $50,354.72 |
DisclosureSEC source: 0001209191-19-045973 · doc4.xml · nonDerivative · entry 4 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 48,792 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $44.50 to $45.46. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 21:38 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 7,700 | $45.59 | $351,043.00 |
DisclosureSEC source: 0001209191-19-045973 · doc4.xml · nonDerivative · entry 3 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,361,310 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $45.42 to $45.90. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 21:38 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 10,700 | $44.98 | $481,286.00 |
DisclosureSEC source: 0001209191-19-045973 · doc4.xml · nonDerivative · entry 2 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,369,010 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $44.42 to $45.41. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 21:38 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 6,834 | $2.90 | $19,818.60 |
DisclosureSEC source: 0001209191-19-045973 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,379,710 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 25, 2019 Filed Jul 26, 2019 21:31 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,834 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-19-043404 · doc4.xml · derivative · entry 12 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,038 Underlying: Common Stock · 6,834 shares Expires 2020-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully vested. Read SEC document |
| July 25, 2019 Filed Jul 26, 2019 21:31 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 100 | $47.90 | $4,790.00 |
DisclosureSEC source: 0001209191-19-043404 · doc4.xml · nonDerivative · entry 8 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 49,910 F1 · kind: Shares sold pursuant to a 10b5-1 plan. Read SEC document |
| July 25, 2019 Filed Jul 26, 2019 21:31 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,318 | $46.80 | $61,682.40 |
DisclosureSEC source: 0001209191-19-043404 · doc4.xml · nonDerivative · entry 7 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 50,010 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F6 · price: The shares were sold at prices ranging from $46.34 to $47.08. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 25, 2019 Filed Jul 26, 2019 21:31 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,900 | $47.72 | $90,668.00 |
DisclosureSEC source: 0001209191-19-043404 · doc4.xml · nonDerivative · entry 6 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,372,876 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F5 · price: The shares were sold at prices ranging from $47.28 to $47.96. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 25, 2019 Filed Jul 26, 2019 21:31 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 16,500 | $46.86 | $773,190.00 |
DisclosureSEC source: 0001209191-19-043404 · doc4.xml · nonDerivative · entry 5 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,374,776 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $46.27 to $47.22. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 25, 2019 Filed Jul 26, 2019 21:31 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 6,834 | $2.90 | $19,818.60 |
DisclosureSEC source: 0001209191-19-043404 · doc4.xml · nonDerivative · entry 4 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,391,276 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 24, 2019 Filed Jul 26, 2019 21:31 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,834 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-19-043404 · doc4.xml · derivative · entry 11 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,872 Underlying: Common Stock · 6,834 shares Expires 2020-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully vested. Read SEC document |
| July 24, 2019 Filed Jul 26, 2019 21:31 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,418 | $46.57 | $66,036.26 |
DisclosureSEC source: 0001209191-19-043404 · doc4.xml · nonDerivative · entry 3 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 51,328 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $46.28 to $46.97. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 24, 2019 Filed Jul 26, 2019 21:31 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 18,400 | $46.54 | $856,336.00 |
DisclosureSEC source: 0001209191-19-043404 · doc4.xml · nonDerivative · entry 2 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,384,442 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $46.20 to $47.01. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 24, 2019 Filed Jul 26, 2019 21:31 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 6,834 | $2.90 | $19,818.60 |
DisclosureSEC source: 0001209191-19-043404 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,402,842 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 11, 2019 Filed Jul 12, 2019 20:27 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,834 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-19-041936 · doc4.xml · derivative · entry 12 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,706 Underlying: Common Stock · 6,834 shares Expires 2020-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully vested. Read SEC document |
| July 11, 2019 Filed Jul 12, 2019 20:27 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,418 | $45.09 | $63,937.62 |
DisclosureSEC source: 0001209191-19-041936 · doc4.xml · nonDerivative · entry 8 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 52,746 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F7 · price: The shares were sold at prices ranging from $44.55 to $45.34. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 11, 2019 Filed Jul 12, 2019 20:27 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 500 | $45.66 | $22,830.00 |
DisclosureSEC source: 0001209191-19-041936 · doc4.xml · nonDerivative · entry 7 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,396,008 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F6 · price: The shares were sold at prices ranging from $45.60 to $45.69. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 11, 2019 Filed Jul 12, 2019 20:27 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 17,900 | $45.14 | $808,006.00 |
DisclosureSEC source: 0001209191-19-041936 · doc4.xml · nonDerivative · entry 6 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,396,508 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F5 · price: The shares were sold at prices ranging from $44.56 to $45.52. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 11, 2019 Filed Jul 12, 2019 20:27 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 6,834 | $2.90 | $19,818.60 |
DisclosureSEC source: 0001209191-19-041936 · doc4.xml · nonDerivative · entry 5 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,414,408 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 10, 2019 Filed Jul 12, 2019 20:27 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,834 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-19-041936 · doc4.xml · derivative · entry 11 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,540 Underlying: Common Stock · 6,834 shares Expires 2020-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully vested. Read SEC document |
| July 10, 2019 Filed Jul 12, 2019 20:27 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,418 | $44.81 | $63,540.58 |
DisclosureSEC source: 0001209191-19-041936 · doc4.xml · nonDerivative · entry 4 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 54,164 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $44.23 to $45.13. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 10, 2019 Filed Jul 12, 2019 20:27 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 6,233 | $45.07 | $280,921.31 |
DisclosureSEC source: 0001209191-19-041936 · doc4.xml · nonDerivative · entry 3 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,407,574 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $45.00 to $45.20. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 10, 2019 Filed Jul 12, 2019 20:27 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 12,167 | $44.66 | $543,378.22 |
DisclosureSEC source: 0001209191-19-041936 · doc4.xml · nonDerivative · entry 2 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,413,807 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $44.035 to $44.99. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 10, 2019 Filed Jul 12, 2019 20:27 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 6,834 | $2.90 | $19,818.60 |
DisclosureSEC source: 0001209191-19-041936 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,425,974 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 20:47 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,834 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-19-038494 · doc4.xml · derivative · entry 12 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,374 Underlying: Common Stock · 6,834 shares Expires 2020-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully vested. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 20:47 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 100 | $45.45 | $4,545.00 |
DisclosureSEC source: 0001209191-19-038494 · doc4.xml · nonDerivative · entry 8 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 55,582 F1 · kind: Shares sold pursuant to a 10b5-1 plan. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 20:47 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,318 | $44.23 | $58,295.14 |
DisclosureSEC source: 0001209191-19-038494 · doc4.xml · nonDerivative · entry 7 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 55,682 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F6 · price: The shares were sold at prices ranging from $44.02 to $44.85. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 20:47 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 2,200 | $45.22 | $99,484.00 |
DisclosureSEC source: 0001209191-19-038494 · doc4.xml · nonDerivative · entry 6 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,419,140 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F5 · price: The shares were sold at prices ranging from $44.92 to $45.48. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 20:47 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 16,200 | $44.28 | $717,336.00 |
DisclosureSEC source: 0001209191-19-038494 · doc4.xml · nonDerivative · entry 5 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,421,340 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $43.92 to $44.865. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 20:47 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 6,834 | $2.90 | $19,818.60 |
DisclosureSEC source: 0001209191-19-038494 · doc4.xml · nonDerivative · entry 4 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,437,540 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 20:47 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,834 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-19-038494 · doc4.xml · derivative · entry 11 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,208 Underlying: Common Stock · 6,834 shares Expires 2020-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully vested. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 20:47 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,418 | $43.99 | $62,377.82 |
DisclosureSEC source: 0001209191-19-038494 · doc4.xml · nonDerivative · entry 3 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 57,000 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $43.695 to $44.59. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 20:47 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 18,400 | $44.02 | $809,968.00 |
DisclosureSEC source: 0001209191-19-038494 · doc4.xml · nonDerivative · entry 2 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,430,706 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $43.60 to $44.60. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.